Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion disclosed its mid-to-long-term management plan, setting revenue targets of KRW 3.5T for 2024 and KRW 5.0T for 2025, while outlining plans for its CDMO business including reviewing the securing of new facilities through subsidiary investment.
📊 [Key Disclosure Details & Financial Highlights]
- Business Status & Mid-to-Long-Term Strategy
- Biosimilar & New Drug Business: Target revenue of KRW 3.5T for 2024 and KRW 5.0T for 2025. Expanding new drug pipelines into ADCs and multi-specific antibodies targeting commercialization by 2029
- CDMO Business: Strengthening capabilities and expanding scale of existing CDMO operations. Reviewing new plant acquisition through equity investment in a subsidiary for new product manufacturing and CDMO business purposes
- Information Provision Details
- Provider: Celltrion IR Team
- Target: Overseas investors
- Date & Time: September 07, 2024 (KST)
- Event: Morgan Stanley Global Healthcare Conference
- Contact: IR Department (+82-1661-8722)
- Other Important Matters
- Details contain forward-looking predictions and are subject to change based on shifts in the business environment or management plans.
- The board resolution and information provision date correspond to the event date.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Revenue Goal Progress and Subsequent Disclosures on CDMO Subsidiary Investments
This filing outlines the company’s mid-to-long-term revenue targets and strategic roadmap for its CDMO business. Tracking whether annual revenue goals are met and verifying if concrete execution plans, such as subsidiary investments for new plant acquisitions, are finalized and disclosed is important for assessing the execution of the company’s long-term growth strategy. Detailed progress can be verified in upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports) and subsequent disclosures on major management matters.
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
